UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| (Address of Principal Executive Offices) (Zip Code) |
||||
| Registrant’s
telephone number, including area code: ( | ||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
On March 28, 2024, GenFleet Therapeutics (Shanghai), Inc. (“GenFleet”), SELLAS Life Science Group Inc.’s partner with respect to the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, announced that it entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to initiate a combination study of GFH009 and BRUKINSA® (zanubrutinib, BTK inhibitor) in a multicenter phase Ib/II trial treating diffuse large B-cell lymphoma (DLBCL) and announced the dosing of the first patient in the trial. According to the announcement, under the terms of the clinical trial collaboration and supply agreement, GenFleet will conduct an open-label, single-arm and multi-center study of the combination therapy to evaluate the safety and efficacy among relapsed/refractory DLBCL patients. The study is being conducted in China.
The information in this Item 8.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SELLAS Life Sciences Group, Inc. | ||||
| Date: | March 28, 2024 | By: | /s/ John T. Burns | |
| Name: | John T. Burns | |||
| Title: | Senior Vice President, Chief Financial Officer | |||
3